In the last few years, Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry. With multiple programs now nearing proof-of ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital ...
Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...
Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...
Drs. A. (Arjen) Maathuis is benoemd tot burgemeester van de gemeente Meppel. De benoeming gaat in op 1 april 2025.
Dit artikel is alleen te lezen voor onze abonnees. Kies voor een van de onderstaande abonnementen om direct verder te lezen.
The impact of this matter on Astellas’ financial results for the fiscal year ending March 31, 2025, is expected to be minor. Eye injections like the one for IZERVAY can cause an eye infection ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback